Bevacizumab Effect on Blood Velocity

The Effect of Intravitreal Bevacizumab (Avastin) Injection on Retinal Blood-Flow Velocity in Patients With Choroidal Neovascularization

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01298440

Enrollment

Registered

2011-02-17

Start date

2008-01-31

Completion date

2008-06-30

Last updated

2011-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Choroidal Neovascularization

Brief summary

Retinal blood flow velocity is affected by Bevacizump intravitreal injection. This effect is correlated to treatment success.

Detailed description

The purpose of the study was to carry out a pilot study on the short-term effect of intravitreal Bevacizumab (Avastin) injection on retinal blood-flow velocity and test whether the short-term haemodynamic changes could predict the longer term clinical result of the treatment.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients with CNV receiving Bevacizumab intravitreal injection

Exclusion criteria

* Candidates in whom the retina could not be seen clearly because of media opacity or a poorly dilating pupil

Design outcomes

Primary

Measure	Time frame
Blood flow velocity change	1 day following injection

Countries

Israel

Outcome results